Senolytic Peptide • Anti-Aging

FOXO4-DRI: The Senescent Cell Killer

By MeetPeptide Research Team

Last updated: March 2026

FOXO4-DRI is a D-retro-inverso peptide that selectively eliminates senescent cells by disrupting the FOXO4-p53 survival interaction. Published in Cell (2017), it restored fitness and organ function in aged mice without harming healthy tissue.

2017
Published in
Cell Journal
p53
Key Target
Protein
D-aa
Retro-Inverso
Protease Resistant
Background

What Is FOXO4-DRI?

Developed by Peter de Keizer's team at Erasmus University Medical Center, FOXO4-DRI is a peptide designed using D-retro-inverso technology — making it resistant to protease degradation while maintaining binding specificity for the FOXO4-p53 interaction.

🎯
FOXO4-p53 Disruption

Senescent cells survive by using FOXO4 to trap p53 in PML nuclear bodies, preventing apoptosis. FOXO4-DRI competes for this binding site, freeing p53 to trigger programmed cell death.

⚡
Selective Apoptosis

Only senescent cells depend on the FOXO4-p53 interaction for survival. Healthy cells use different anti-apoptotic mechanisms, giving FOXO4-DRI theoretical selectivity.

🧬
D-Retro-Inverso Design

Uses D-amino acids in reverse sequence to resist protease degradation while maintaining the side-chain topology needed for target binding. This extends bioavailability.

🔥
SASP Reduction

By eliminating senescent cells, FOXO4-DRI reduces the senescence-associated secretory phenotype (SASP) — the inflammatory cocktail that damages surrounding healthy tissue.

Research

What the Research Shows

📋

Context: The landmark 2017 Cell paper by Baar et al. is the primary study. Subsequent work has expanded into specific tissue models. No human clinical trials exist — this remains preclinical research.

Aged Mice — Tissue Homeostasis (Baar et al., Cell 2017)
Restored fur density, renal function, and fitness in naturally aged mice
Positive
Chemotoxicity Rescue — Doxorubicin Model
Neutralized doxorubicin-induced chemotoxicity and liver damage in mice
Positive
Senescent Chondrocytes (In Vitro)
Selectively removed senescent cells from expanded human chondrocyte cultures
Positive
Leydig Cell Senescence — Testosterone Restoration
Cleared senescent Leydig cells and improved testosterone secretion in aged mice
Positive
Safety

Side Effects & Safety Profile

Healthy Tissue Impact
No reported toxicity to healthy (non-senescent) cells in animal models
Favorable
Transient Diarrhea
Mild GI effects observed at high doses in some mouse studies
Mild
Human Safety Data
No human clinical trials have been conducted
Unknown
Sources

Study Citations

Landmark Study
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Baar MP, Brandt RMC, Putavet DA, et al. · Cell, 2017;169(1):132-147 · PMC5556182
Structural Study
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Nature Communications, 2025 · doi: 10.1038/s41467-025-60844-9
In Vitro
Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Frontiers in Bioengineering, 2021 · PMC8116695
Reproductive Aging
FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Aging, 2020 · doi: 10.18632/aging.102682

Self-Assessment

Who Researches FOXO4-DRI?

This Research Is Commonly Explored By People Who...

  • Are deeply interested in the biology of cellular senescence and aging
  • Want to understand targeted senolytic approaches beyond dasatinib+quercetin
  • Follow longevity research and want to track the cutting edge of anti-aging peptides
  • Are interested in the p53 pathway and its role in aging vs cancer

This Research May Not Be Relevant If...

  • You want something with human clinical trial data — FOXO4-DRI has none
  • You expect an off-the-shelf anti-aging solution — this is early-stage research
  • You're not comfortable with peptides that have only animal model evidence
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.


Get the Guide →
⚕️ Disclaimer: This is educational content, not medical advice. Always consult a healthcare provider before making decisions about your health.
Bottom Line

Key Takeaways

✅ What We Know
  • Selectively kills senescent cells via FOXO4-p53 disruption
  • Restored fitness, fur, and organ function in aged mice
  • D-retro-inverso design resists protease degradation
  • Published in Cell — top-tier peer review
  • Structural basis now mapped (Nature Comms 2025)
⚠️ What We Don't Know
  • Zero human clinical trial data
  • Long-term effects of repeated senescent cell clearance unknown
  • Optimal dosing protocol not established for humans
  • Potential off-target effects in complex human biology
  • Cost and manufacturing challenges remain

🔬 Verified Research Source

Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.

🧬 FOXO4-DRI Buy from Swiss Chems — Lab-tested, verified purity → Shop Now

Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.

Related Resources

🧬
Epitalon Guide
Telomerase-activating peptide
→ 🛡️
Vilon Guide
Immune bioregulator peptide
→ ⚡
Testagen Guide
Testicular bioregulator
→ 🩹
BPC-157 Guide
Healing peptide research
→
⚠️ Disclaimer

FOXO4-DRI is NOT FDA approved and has no human clinical trial data. It is available only for research purposes. This page is for educational purposes only. Not medical advice. Research Only